Literature DB >> 22465911

Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial.

Ugo Pastorino1, Marta Rossi, Valentina Rosato, Alfonso Marchianò, Nicola Sverzellati, Carlo Morosi, Alessandra Fabbri, Carlotta Galeone, Eva Negri, Gabriella Sozzi, Giuseppe Pelosi, Carlo La Vecchia.   

Abstract

The efficacy and cost-effectiveness of low-dose spiral computed tomography (LDCT) screening in heavy smokers is currently under evaluation worldwide. Our screening program started with a pilot study on 1035 volunteers in Milan in 2000 and was followed up in 2005 by a randomized trial comparing annual or biennial LDCT with observation, named Multicentric Italian Lung Detection. This included 4099 participants, 1723 randomized to the control group, 1186 to biennial LDCT screening, and 1190 to annual LDCT screening. Follow-up was stopped in November 2011, with 9901 person-years for the pilot study and 17 621 person-years for Multicentric Italian Lung Detection. Forty-nine lung cancers were detected by LDCT (20 in biennial and 29 in the annual arm), of which 17 were identified at baseline examination; 63% were of stage I and 84% were surgically resectable. Stage distribution and resection rates were similar in the two LDCT arms. The cumulative 5-year lung cancer incidence rate was 311/100 000 in the control group, 457 in the biennial, and 620 in the annual LDCT group (P=0.036); lung cancer mortality rates were 109, 109, and 216/100 000 (P=0.21), and total mortality rates were 310, 363, and 558/100 000, respectively (P=0.13). Total mortality in the pilot study was similar to that observed in the annual LDCT arm at 5 years. There was no evidence of a protective effect of annual or biennial LDCT screening. Furthermore, a meta-analysis of the four published randomized trials showed similar overall mortality in the LDCT arms compared with the control arm.

Entities:  

Mesh:

Year:  2012        PMID: 22465911     DOI: 10.1097/CEJ.0b013e328351e1b6

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  112 in total

1.  Screening for lung cancer with low-dose computed tomography.

Authors:  Anthony B Miller
Journal:  Oncologist       Date:  2013-08-05

Review 2.  Screening for lung cancer with low-dose computed tomography: a review of current status.

Authors:  Henry M Marshall; Rayleen V Bowman; Ian A Yang; Kwun M Fong; Christine D Berg
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

3.  Inequivalence of non-aggressiveness in clinically diagnosed lung cancers and overdiagnosis in lung cancer screening trials.

Authors:  Jerome M Reich; Jong S Kim
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  Characterization of Individuals Taking Part in Low Dose Computed Tomography (LDCT) Screening Program.

Authors:  Mariann Moizs; Gábor Bajzik; Zsuzsanna Lelovics; János Strausz; Marianna Rakvács; Péter Zádori; Árpád Kovács; Imre Repa
Journal:  Pathol Oncol Res       Date:  2015-05-25       Impact factor: 3.201

Review 5.  Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals.

Authors:  Jiu-Wei Cui; Wei Li; Fu-Jun Han; Yu-Di Liu
Journal:  Transl Lung Cancer Res       Date:  2015-06

Review 6.  Lung cancer screening-low dose CT for lung cancer screening: recent trial results and next steps.

Authors:  Emma Louise O'Dowd; David R Baldwin
Journal:  Br J Radiol       Date:  2017-10-17       Impact factor: 3.039

Review 7.  Efficacy of low-dose computed tomography screening for lung cancer: the current state of evidence of mortality reduction.

Authors:  Motoyasu Sagawa; Takafumi Sugawara; Naoya Ishibashi; Akira Koyanagi; Takashi Kondo; Toshiharu Tabata
Journal:  Surg Today       Date:  2016-11-04       Impact factor: 2.549

Review 8.  Implementing lung cancer screening in the real world: opportunity, challenges and solutions.

Authors:  Robert J Optican; Caroline Chiles
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 9.  MicroRNA as tools and therapeutics in lung cancer.

Authors:  Jennifer F Barger; S Patrick Nana-Sinkam
Journal:  Respir Med       Date:  2015-02-19       Impact factor: 3.415

10.  Assessing the benefits and harms of low-dose computed tomography screening for lung cancer.

Authors:  Paul F Pinsky
Journal:  Lung Cancer Manag       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.